Found 295 articles for: "alopecia"
Hydroxychloroquine-Induced Nonthrombocytopenic Purpura: A Case Series
May 2024 | Volume 23 | Issue 5 | Case Reports | 7781 | Copyright © May 2024
Hydroxychloroquine (HCQ) is a disease-modifying anti-rheumatic medication for the treatment of various autoimmune conditions. A rare side effect of HCQ is thrombotic thrombocytopenic purpura (TTP). We...
Read MoreExpression of IL-4 in Tumors: A Safety Surrogate to Predict Cancer Survival Associated With Biologic Therapies
April 2024 | Volume 23 | Issue 4 | Editorials | e118 | Copyright © April 2024
Mitogen-Activated Protein Kinase Inhibitor-Induced Inflammatory Alopecia in Woman With Ovarian Cancer
April 2024 | Volume 23 | Issue 4 | Case Reports | e102 | Copyright © April 2024
Inflammatory alopecia is an increasingly reported side effect of targeted cancer therapies. Here we report one case of inflammatory alopecia secondary to mitogen-activated protein kinase kinase (...
Read MoreBeyond Wrinkles: A Comprehensive Review of the Uses of Botulinum Toxin
March 2024 | Volume 23 | Issue 3 | Original Article | 173 | Copyright © March 2024
Background: Botulinum neurotoxin (BoNT) exhibits inhibitory effects on the neuromuscular junction, and its use is well established in cosmetic dermatology. Our review aims to ana...
Read MoreHighlighting the Link Between Lichen Planus Pigmentosus and Frontal Fibrosing Alopecia
March 2024 | Volume 23 | Issue 3 | Features | 196 | Copyright © March 2024
Efficacy of Low-Dose Spironolactone for Hair Loss in Women
March 2024 | Volume 23 | Issue 3 | Editorials | e91 | Copyright © March 2024
Safety and Efficacy of Minoxidil Treatment in Scarring Alopecia: A Scoping Review
March 2024 | Volume 23 | Issue 3 | Original Article | 146 | Copyright © March 2024
Background: Topical minoxidil (TM) has been a cornerstone in treating various hair loss disorders, while low-dose oral minoxidil (LDOM) is emerging as an effective alternative. D...
Read MoreSurvey of the Prices of Topical Compounded Medications for Alopecia in the Tri-State Area
March 2024 | Volume 23 | Issue 3 | Original Article | 168 | Copyright © March 2024
Background: Currently, there is only one topical medication approved by the U.S. Food and Drug Administration for alopecia, minoxidil 2.5% and 5%. With limited options, dermatolo...
Read MoreSurvey of Dermatology Practitioners' Opinions and Prescribing Habits of Oral Minoxidil for the Treatment of Androgenetic Alopecia
March 2024 | Volume 23 | Issue 3 | Original Article | 136 | Copyright © March 2024
Background: Utilization of low-dose oral minoxidil has increased in recent years in association with several clinical studies that have shown its efficacy in treating androgeneti...
Read MoreExamining the Uncertainties Surrounding Exosome Therapy in Androgenetic Alopecia: A Call for Evidence-Based Practice
March 2024 | Volume 23 | Issue 3 | Features | e86 | Copyright © March 2024
Hair loss, a pervasive and often distressing condition, affects a substantial number of individuals globally. Although conventional treatments such as hair transplantation, topicals, oral medicat...
Read MoreFactors Impacting New Drug Adoption in the Clinical Setting: A Survey of Dermatologists
January 2024 | Volume 23 | Issue 1 | Editorials | 1362 | Copyright © January 2024
The 200-Year Timeline on Botulinum Toxin: From Biologic Poison to Wonder Drug
January 2024 | Volume 23 | Issue 1 | Features | 1357 | Copyright © January 2024
The history of botulinum toxin dates back to the late 1700s, when food preparation, storage, and later canning practices led to outbreaks of botulism across Europe and the United States. It is fr...
Read MoreOral Minoxidil Media Coverage: The Impact on Patient Perceptions and Practitioner Approaches to Androgenetic Alopecia
January 2024 | Volume 23 | Issue 1 | Editorials | 1364 | Copyright © January 2024
Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases
December 2023 | Volume 22 | Issue 12 | Original Article | 1183 | Copyright © December 2023
Dysregulation of Janus kinase (JAK) pathways from uncontrolled cytokine signaling comprises the pathological basis for many complex inflammatory cutaneous disorders. Oral JAK inhibitors, upadacit...
Read MoreInternational Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual Meeting
December 2023 | Volume 22 | Issue 12 | Original Article | 1153 | Copyright © December 2023
Background: The International Dermatology Outcome Measures (IDEOM) is a non-profit organization dedicated to the advancement of evidence-based, consensus-driven outcome measures ...
Read MoreINDIVIDUAL ARTICLE: USCOM Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events
November 2023 | Volume 22 | Issue 11 | Supplement Individual Articles | SF389716s4 | Copyright © November 2023
Background: In 2023, nearly 2 million patients will be diagnosed with cancer in the United States and at least 40% will be eligible for treatment with an immune checkpoint inhibi...
Read MorePlatelet-Rich Plasma Across the Spectrum of Alopecias: Where Are We Now?
November 2023 | Volume 22 | Issue 11 | Features | 1134 | Copyright © November 2023
The Potential Impact of Off-Label Medication Use on Patient Access: A Cross-Sectional Survey of Minoxidil Availability
January 2024 | Volume 23 | Issue 1 | Editorials | 1360 | Copyright © January 2024
A Review of the Current Landscape of Hidradenitis Suppurativa Treatment Development
October 2023 | Volume 22 | Issue 10 | Original Article | 1021 | Copyright © October 2023
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent nodules and abscesses leading to subsequent scarring and tunnel form...
Read MoreSuccessful Treatment of Lichen Planus With Oral Upadacitinib
October 2023 | Volume 22 | Issue 10 | Case Reports | 1058 | Copyright © October 2023
Media and other results for: "alopecia"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
